Staphylococcus Aureus Bacteremia in Patients on Chronic Hemodialysis

Leigh Quarles, Edwin A. Rutsky, Stephen G. Rostand

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Staphylococcus aureus bacteremia occurred 96 times in 58 of 671 patients on chronic hemodialysis during a nine-year period. Seventy-one instances of bacteremia originated in the vascular access site and resulted in the loss of the access device in 45 episodes. The overall mortality was 8%, and the incidence of infective endocarditis was 4%. Death occurred more often when bacteremia arose from an identifiable site other than the vascular access device (P㰠.02). Patients who developed one or more metastatic foci of infection had a higher incidence of primary treatment failure (P 㰠01) and a higher mortality (P 㰠) than did those with no metastatic infection. Although meaningful comparisons of differing antibiotic regimens could not be made, patients receiving antibiotic therapy for 28 days or longer relapsed less frequently (P 㰠.05) These data suggest that chronic hemodialysis patients with S aureus bacteremia have a relatively low mortality and a low risk of infective endocarditis. Antibiotic treatment, however, should be given for at least 28 days in order to minimize the risk of relapse.

Original languageEnglish (US)
Pages (from-to)412-419
Number of pages8
JournalAmerican Journal of Kidney Diseases
Volume6
Issue number6
DOIs
StatePublished - Jan 1 1985
Externally publishedYes

Fingerprint

Bacteremia
Renal Dialysis
Staphylococcus aureus
Anti-Bacterial Agents
Endocarditis
Mortality
Vascular Access Devices
Incidence
Infection
Treatment Failure
Blood Vessels
Recurrence
Equipment and Supplies
Therapeutics

All Science Journal Classification (ASJC) codes

  • Nephrology

Cite this

Staphylococcus Aureus Bacteremia in Patients on Chronic Hemodialysis. / Quarles, Leigh; Rutsky, Edwin A.; Rostand, Stephen G.

In: American Journal of Kidney Diseases, Vol. 6, No. 6, 01.01.1985, p. 412-419.

Research output: Contribution to journalArticle

Quarles, Leigh ; Rutsky, Edwin A. ; Rostand, Stephen G. / Staphylococcus Aureus Bacteremia in Patients on Chronic Hemodialysis. In: American Journal of Kidney Diseases. 1985 ; Vol. 6, No. 6. pp. 412-419.
@article{bc704e7fad1145cdb0fb949d8e1286af,
title = "Staphylococcus Aureus Bacteremia in Patients on Chronic Hemodialysis",
abstract = "Staphylococcus aureus bacteremia occurred 96 times in 58 of 671 patients on chronic hemodialysis during a nine-year period. Seventy-one instances of bacteremia originated in the vascular access site and resulted in the loss of the access device in 45 episodes. The overall mortality was 8{\%}, and the incidence of infective endocarditis was 4{\%}. Death occurred more often when bacteremia arose from an identifiable site other than the vascular access device (P㰠.02). Patients who developed one or more metastatic foci of infection had a higher incidence of primary treatment failure (P 㰠01) and a higher mortality (P 㰠) than did those with no metastatic infection. Although meaningful comparisons of differing antibiotic regimens could not be made, patients receiving antibiotic therapy for 28 days or longer relapsed less frequently (P 㰠.05) These data suggest that chronic hemodialysis patients with S aureus bacteremia have a relatively low mortality and a low risk of infective endocarditis. Antibiotic treatment, however, should be given for at least 28 days in order to minimize the risk of relapse.",
author = "Leigh Quarles and Rutsky, {Edwin A.} and Rostand, {Stephen G.}",
year = "1985",
month = "1",
day = "1",
doi = "10.1016/S0272-6386(85)80104-9",
language = "English (US)",
volume = "6",
pages = "412--419",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Staphylococcus Aureus Bacteremia in Patients on Chronic Hemodialysis

AU - Quarles, Leigh

AU - Rutsky, Edwin A.

AU - Rostand, Stephen G.

PY - 1985/1/1

Y1 - 1985/1/1

N2 - Staphylococcus aureus bacteremia occurred 96 times in 58 of 671 patients on chronic hemodialysis during a nine-year period. Seventy-one instances of bacteremia originated in the vascular access site and resulted in the loss of the access device in 45 episodes. The overall mortality was 8%, and the incidence of infective endocarditis was 4%. Death occurred more often when bacteremia arose from an identifiable site other than the vascular access device (P㰠.02). Patients who developed one or more metastatic foci of infection had a higher incidence of primary treatment failure (P 㰠01) and a higher mortality (P 㰠) than did those with no metastatic infection. Although meaningful comparisons of differing antibiotic regimens could not be made, patients receiving antibiotic therapy for 28 days or longer relapsed less frequently (P 㰠.05) These data suggest that chronic hemodialysis patients with S aureus bacteremia have a relatively low mortality and a low risk of infective endocarditis. Antibiotic treatment, however, should be given for at least 28 days in order to minimize the risk of relapse.

AB - Staphylococcus aureus bacteremia occurred 96 times in 58 of 671 patients on chronic hemodialysis during a nine-year period. Seventy-one instances of bacteremia originated in the vascular access site and resulted in the loss of the access device in 45 episodes. The overall mortality was 8%, and the incidence of infective endocarditis was 4%. Death occurred more often when bacteremia arose from an identifiable site other than the vascular access device (P㰠.02). Patients who developed one or more metastatic foci of infection had a higher incidence of primary treatment failure (P 㰠01) and a higher mortality (P 㰠) than did those with no metastatic infection. Although meaningful comparisons of differing antibiotic regimens could not be made, patients receiving antibiotic therapy for 28 days or longer relapsed less frequently (P 㰠.05) These data suggest that chronic hemodialysis patients with S aureus bacteremia have a relatively low mortality and a low risk of infective endocarditis. Antibiotic treatment, however, should be given for at least 28 days in order to minimize the risk of relapse.

UR - http://www.scopus.com/inward/record.url?scp=0022350958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022350958&partnerID=8YFLogxK

U2 - 10.1016/S0272-6386(85)80104-9

DO - 10.1016/S0272-6386(85)80104-9

M3 - Article

VL - 6

SP - 412

EP - 419

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 6

ER -